has function has role vaccinated in route immunizes against disease immunizes recipient cancer Homo sapiens intramuscular route therapeutic vaccine function vaccine in clinical trial role therapeutic cancer vaccine whole cell cancer vaccine NY-ESO-1, MAGE-A1, and MAGE-A3 dendritic cell vaccine NCT: https://clinicaltrials.gov/study/NCT02332889 Gene name: MAGE-A1 Gene name: MAGE-A3 Gene name: NY-ESO-1 Hayleigh Kahn 4100 A cancer vaccine that is made from the subject's blood cells and is designed to interact in the patient's body with cells that are programmed to fight specific tumor proteins NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma Antigen Gene-A3 (MAGE-A3). The vaccine can be given in combination with decitabine which may increase the amount and activity of these cancer proteins on the surface of tumor cells to increase the possibility that the vaccine will stimulate cells to act against the tumor cells. The dendritic cells may stimulate CD4 and CD8 antigen specific T cells in patients with relapsed or refractory pediatric high grade gliomas, medulloblastomas, and central nervous system primitive neuroectodermal tumors (CNS PNETs). 4102 1485 6367 Jie Zheng VIOLIN: https://violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=6367 cancer vaccine